Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
casdatifan + ivonescimab
- Development stage
- Unknown
- Lead developer
- Arcus Biosciences
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Casdatifan plus ivonescimab is an investigational combination regimen being evaluated for the treatment of clear cell renal cell carcinoma (ccRCC), including first-line metastatic disease. Casdatifan (AB521) is an oral, once-daily small-molecule inhibitor of hypoxia-inducible factor 2-alpha (HIF-2α) developed by Arcus Biosciences. Ivonescimab (SMT112/AK112) is an investigational humanized tetravalent bispecific antibody developed by Akeso and licensed to Summit Therapeutics, which simultaneously targets programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF). Under a clinical trial collaboration announced in 2026, Arcus sponsors and conducts the combination study as a new cohort within its ARC-20 platform trial, with Summit supplying ivonescimab. The combination aims to provide a well-tolerated, tyrosine kinase inhibitor (TKI)-sparing treatment option for patients with advanced kidney cancer.
- Other names
- casdatifan plus ivonescimab
02
Targets
EPAS1 (Hypoxia-inducible factor 2-alpha)PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on casdatifan + ivonescimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on casdatifan + ivonescimab.